Funded Biotechnology Startups in Newcastle Upon Tyne
Biotechnology funding in Newcastle Upon Tyne shows one clear size outlier: Iksuda Therapeutics raised $48M on 2021-06-07, which is far above the other disc…
Biotechnology funding in Newcastle Upon Tyne shows one clear size outlier: Iksuda Therapeutics raised $48M on 2021-06-07, which is far above the other disclosed rounds (the next-largest disclosed amount is $20M for QuantuMDx Group on 2021-11-08). Another outlier in the opposite direction is the smallest disclosed round, PulmoBiomed’s $880K on 2024-02-08.
The 10 most recent rows (from 2021-06-07 through 2025-12-18) cluster heavily in the mid-2020s: four entries land in 2024 (2024-12-05, 2024-09-11, 2024-09-03, 2024-02-08) plus one in 2025 (GlycanAge on 2025-12-18). Stage disclosure is mixed: “Series Unknown” appears in 4 of 10 rows (GlycanAge 2025-12-18, Newcells Biotech 2024-12-05, NunaBio 2024-09-11, Hexis Lab 2023-05-16), while the remaining rows are split across Seed and a single “Venture - Series Unknown” (QuantuMDx Group, 2021-11-08).
Most recent rounds
10 shownRelated listings
Frequently asked
What stands out on deal size in this Newcastle biotech list, and how extreme is it?
Iksuda Therapeutics’ $48M (2021-06-07) dwarfs the rest of the disclosed amounts; the next-highest disclosed round is QuantuMDx Group’s $20M (2021-11-08), with most other entries clustered between $610K and $9M (e.g., GlycanAge $9M on 2025-12-18; Hexis Lab $610K on 2023-05-16).
Do the most recent rounds cluster into a narrow time window?
Yes. Five of the 10 rows fall in 2024–2025, including GlycanAge’s $9M on 2025-12-18 and four separate 2024 entries (Newcells Biotech $2M on 2024-12-05; NunaBio $1M on 2024-09-11; ScubaTx $2M on 2024-09-03; PulmoBiomed $880K on 2024-02-08).
How much of the dataset uses “Series Unknown,” and does it change where the biggest rounds appear?
“Series Unknown” shows up in 4 of 10 rows: GlycanAge ($9M, 2025-12-18), Newcells Biotech ($2M, 2024-12-05), NunaBio ($1M, 2024-09-11), and Hexis Lab ($610K, 2023-05-16). The largest round ($48M, Iksuda Therapeutics on 2021-06-07) is not labeled “Series Unknown” in the table, which instead leaves the biggest disclosed amount outside that label.
Which stage labels dominate, and how are they distributed across time?
Seed appears in 3 of the 10 rows (InvenireX $3M on 2025-11-22; ScubaTx $2M on 2024-09-03; PulmoBiomed $880K on 2024-02-08). The “Venture - Series Unknown” label appears once (QuantuMDx Group, $20M on 2021-11-08), while “Series Unknown” covers 4 rows spread across 2023–2025 (Hexis Lab 2023-05-16 through GlycanAge 2025-12-18).
Are there notable outliers besides the largest check, especially at the low end?
PulmoBiomed’s $880K (2024-02-08) is the smallest disclosed amount in the list, sitting below MarraBio’s $620K (2023-09-18) would be smaller if that were disclosed as $620K, but the table shows MarraBio $620K, making MarraBio actually the lowest disclosed amount among the rows. Either way, the low-end cluster is well separated from the top: QuantuMDx Group’s $20M (2021-11-08) and Iksuda Therapeutics’ $48M (2021-06-07) are multiple times above the sub-$1.0M entries (e.g., MarraBio $620K on 2023-09-18; Hexis Lab $610K on 2023-05-16).
What’s the most recent entry and where do the rounds begin in the table’s date span?
The most recent round date shown is 2025-12-18 for GlycanAge at $9M. The date span runs back to 2021-06-07 for Iksuda Therapeutics at $48M, with the remaining rows filling 2021–2024 (e.g., QuantuMDx Group 2021-11-08 $20M; MarraBio 2023-09-18 $620K; Newcells Biotech 2024-12-05 $2M).
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.